Relmada Therapeutics (RLMD) Earnings Date, Estimates & Call Transcripts $0.59 -0.01 (-1.48%) As of 12:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Relmada Therapeutics Earnings Summary Relmada Therapeutics released Q2 2025 earnings on August 7, 2025, reporting an EPS of -$0.30, which missed analysts' consensus estimates of -$0.25 by $0.05. With a trailing EPS of -$2.51, Relmada Therapeutics' earnings are expected to grow next year, from ($2.73) to ($0.63) per share. Latest Q2 Earnings DateAug. 7EstimatedConsensus EPS (Aug. 7) -$0.25 Actual EPS (Aug. 7) -$0.30 Missed By -$0.05 Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Relmada Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relmada Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRLMD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Relmada Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.10-$0.10-$0.10Q2 20251-$0.04-$0.04-$0.04Q3 20251-$0.04-$0.04-$0.04Q4 20251-$0.03-$0.03-$0.03 Relmada Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025-$0.25-$0.30 -$0.05-$0.30--5/12/2025Q1 2025-$0.31-$0.58 -$0.27-$0.58--3/27/2025Q4 2024-$0.70-$0.62+$0.08-$0.62--11/7/2024Q3 2024-$0.65-$0.72 -$0.07-$0.72--8/7/2024Q2 2024-$0.83-$0.59+$0.24-$0.59--5/8/2024Q1 2024-$0.90-$0.72+$0.18-$0.72--3/19/2024Q4 2023-$0.88-$0.84+$0.04-$0.84--11/8/2023Q3 2023-$0.95-$0.73+$0.22-$0.73--8/8/2023Q2 2023-$0.92-$0.84+$0.08-$0.84-- Relmada Therapeutics Earnings - Frequently Asked Questions When did Relmada Therapeutics announce their last quarterly earnings? Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earning data on Thursday, August 7, 2025. Learn more on RLMD's earnings history. Did Relmada Therapeutics beat their earnings estimates last quarter? In the previous quarter, Relmada Therapeutics (NASDAQ:RLMD) missed the analysts' consensus estimate of ($0.25) by $0.05 with a reported earnings per share (EPS) of ($0.30). Learn more on analysts' earnings estimate vs. RLMD's actual earnings. How can I listen to Relmada Therapeutics' earnings conference call? The conference call for Relmada Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Relmada Therapeutics' conference call transcript? The conference call transcript for Relmada Therapeutics' latest earnings report can be read online. Read Transcript How much profit does Relmada Therapeutics generate each year? Relmada Therapeutics (NASDAQ:RLMD) has a recorded net income of -$79.98 million. RLMD has generated -$2.51 earnings per share over the last four quarters. What is Relmada Therapeutics' EPS forecast for next year? Relmada Therapeutics' earnings are expected to grow from ($2.73) per share to ($0.63) per share in the next year. More Earnings Resources from MarketBeat Related Companies Entera Bio Earnings Date Milestone Pharmaceuticals Earnings Date Cabaletta Bio Earnings Date Quince Therapeutics Earnings Date eXoZymes Earnings Date ESSA Pharma Earnings Date Alto Neuroscience Earnings Date Scilex Earnings Date Elutia Earnings Date CervoMed Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a RallyRivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk Production This page (NASDAQ:RLMD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts